Growth-Hormone & Body-Composition Research
Tesamorelin 10mg
Tesamorelin 10mg
Connect GHRF signalling to visceral-fat research.
A GHRF analogue studied across growth-hormone signalling, IGF-1 response and visceral-adipose biology.
- Documentation
- Check batch record
- Availability
- In stock
For qualified laboratory research only · Not for human or veterinary use
Why researchers choose it
Tesamorelin is a stabilised growth-hormone-releasing-factor analogue that stimulates the pituitary GH pathway, supporting research into downstream IGF-1 response and visceral-adipose biology.
Research focus
- GHRF and pituitary GH signalling
- IGF-1 response research
- Visceral-adipose pathway models
Evidence snapshot
Regulated tesamorelin products have a narrow HIV-lipodystrophy indication and are explicitly not general weight-loss medicines. That approval does not transfer to this 10mg research vial.
Best suited to
For qualified endocrine and adipose-signalling research; no clinical-use protocol is supplied.
Research focus describes published study domains, not a guaranteed outcome. No human or veterinary dosing, reconstitution or administration instructions are supplied.
Related research compounds
GH & Body CompositionA long-acting GHRH analogue studied for sustained growth-hormone and IGF-1 signalling in endocrine research.
GH & Body Composition10mg
A selective ghrelin-receptor agonist studied for controlled growth-hormone release and secretagogue pharmacology.